Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Marc A Riedl, Raffi Tachdjian, William R Lumry, Timothy Craig, Gül Karakaya, Asli Gelincik, Marcin Stobiecki, Joshua S Jacobs, Nihal M Gokmen, Avner Reshef, Mark M Gompels, Michael E Manning, Laura Bordone, Kenneth B Newman, Sabrina Treadwell, Sophie Wang, Aaron Yarlas, Danny M Cohn
BACKGROUND: Hereditary angioedema is a rare disorder characterized by episodic, potentially life-threatening swelling caused by kallikrein-kinin dysregulation. Long-term prophylaxis can stabilize this system. Donidalorsen, an antisense oligonucleotide, specifically reduces prekallikrein expression. METHODS: In this phase 3, double-blind, randomized trial, we assigned patients with hereditary angioedema to receive donidalorsen (80 mg subcutaneously) or placebo once every 4 or 8 weeks...
May 31, 2024: New England Journal of Medicine
#22
JOURNAL ARTICLE
Fatima Azam, Muhammad Hamza Dawood, Aroosa Roshan, Maryam Urooj, Zoha Khan, Muhammad Omar Larik, Fatima Mustafa Lakdawala, Ahad Yousuf Moulvi, Ifrah Salim, Mehak Abbas Zaidi, Alizeh Imran
Aim: We analyzed the 100 most-cited articles on all anti-diabetic drugs. A comprehensive literature review found no bibliometrics on this. Methods: Two researchers independently extracted articles from Scopus and ranked them by citation count as the 'top 100 most-cited'. Results: The median number of citations is 1385.5. Most articles are from the USA (n = 59). Insulin has the most papers (n = 24). Majority (n = 76) were privately funded and contained at least one conflict of interest (n = 66)...
2024: Future Science OA
#23
JOURNAL ARTICLE
Sabrina A Assoumou, Haley V Bonilla, Lillian Vautour, Caitlin White, Amanda Read Newcomb, David Kibbe, John Goldie, Alison Merrill, Melissa Monahan, Benjamin P Linas, Mari-Lynn Drainoni, Cassandra M Pierre, Robert Graham
Health systems could play an important role in efforts to build vaccine confidence in communities that have been hardest hit by Covid-19. Boston Medical Center (BMC) health system, New England's largest safety-net hospital, along with its community partners, implemented a Covid Response Program aimed at building vaccine confidence. The program was supported by a multifaceted and multilingual communications campaign including: 1) traditional and social media channels with trusted messengers, 2) consistent and accessible core messaging, 3) transparent dialogue, and 4) partnership with state and local health government officials...
February 2024: NEJM catalyst innovations in care delivery
#24
JOURNAL ARTICLE
Thomas Beaney, Jonathan Clarke, David Salman, Thomas Woodcock, Azeem Majeed, Paul Aylin, Mauricio Barahona
BACKGROUND: Identifying clusters of diseases may aid understanding of shared aetiology, management of co-morbidities, and the discovery of new disease associations. Our study aims to identify disease clusters using a large set of long-term conditions and comparing methods that use the co-occurrence of diseases versus methods that use the sequence of disease development in a person over time. METHODS: We use electronic health records from over ten million people with multimorbidity registered to primary care in England...
May 29, 2024: Commun Med (Lond)
#25
JOURNAL ARTICLE
Daniel G Bichet, Detlef Bockenhauer
New England Journal of Medicine, Volume 390, Issue 20, Page 1922-1924, May 30, 2024.
May 30, 2024: New England Journal of Medicine
#26
JOURNAL ARTICLE
Demetre C Daskalakis, Howard M Heller, Erica S Shenoy, Katherine Hsu
New England Journal of Medicine, Volume 390, Issue 20, Page 1906-1912, May 30, 2024.
May 30, 2024: New England Journal of Medicine
#27
JOURNAL ARTICLE
Rose Olson, Anand Vaidya, Khin-Kyemon Aung, Lauren E Merz, Arielle Langer
New England Journal of Medicine, Volume 390, Issue 20, May 30, 2024.
May 30, 2024: New England Journal of Medicine
#28
JOURNAL ARTICLE
Gregory King, Garry W Hamilton
New England Journal of Medicine, Volume 390, Issue 20, May 30, 2024.
May 30, 2024: New England Journal of Medicine
#29
JOURNAL ARTICLE
Zhi Hu, Dan Liu
New England Journal of Medicine, Volume 390, Issue 20, May 30, 2024.
May 30, 2024: New England Journal of Medicine
#30
REVIEW
Kun-Hsing Yu, Elizabeth Healey, Tze-Yun Leong, Isaac S Kohane, Arjun K Manrai
New England Journal of Medicine, Volume 390, Issue 20, Page 1895-1904, May 30, 2024.
May 30, 2024: New England Journal of Medicine
#31
JOURNAL ARTICLE
Vasileios Oikonomou, Grace Smith, Gregory M Constantine, Monica M Schmitt, Elise M N Ferré, Julie C Alejo, Deanna Riley, Dhaneshwar Kumar, Lucas Dos Santos Dias, Joseph Pechacek, Yannis Hadjiyannis, Taura Webb, Bryce A Seifert, Rajarshi Ghosh, Magdalena Walkiewicz, Daniel Martin, Marine Besnard, Brendan D Snarr, Shiva Deljookorani, Chyi-Chia R Lee, Tom DiMaggio, Princess Barber, Lindsey B Rosen, Aristine Cheng, Andre Rastegar, Adriana A de Jesus, Jennifer Stoddard, Hye Sun Kuehn, Timothy J Break, Heidi H Kong, Leslie Castelo-Soccio, Ben Colton, Blake M Warner, David E Kleiner, Martha M Quezado, Jeremy L Davis, Kevin P Fennelly, Kenneth N Olivier, Sergio D Rosenzweig, Anthony F Suffredini, Mark S Anderson, Marc Swidergall, Carole Guillonneau, Luigi D Notarangelo, Raphaela Goldbach-Mansky, Olaf Neth, Maria Teresa Monserrat-Garcia, Justo Valverde-Fernandez, Jose Manuel Lucena, Ana Lucia Gomez-Gila, Angela Garcia Rojas, Mikko R J Seppänen, Jouko Lohi, Matti Hero, Saila Laakso, Paula Klemetti, Vanja Lundberg, Olov Ekwall, Peter Olbrich, Karen K Winer, Behdad Afzali, Niki M Moutsopoulos, Steven M Holland, Theo Heller, Stefania Pittaluga, Michail S Lionakis
BACKGROUND: Autoimmune polyendocrine syndrome type 1 (APS-1) is a life-threatening, autosomal recessive syndrome caused by autoimmune regulator (AIRE) deficiency. In APS-1, self-reactive T cells escape thymic negative selection, infiltrate organs, and drive autoimmune injury. The effector mechanisms governing T-cell-mediated damage in APS-1 remain poorly understood. METHODS: We examined whether APS-1 could be classified as a disease mediated by interferon-γ...
May 30, 2024: New England Journal of Medicine
#32
REVIEW
Mario Cristancho, Maurizio Fava, Julie Ingelfinger, Sina Nikayin, Gerard Sanacora
New England Journal of Medicine, Volume 390, Issue 20, May 30, 2024.
May 30, 2024: New England Journal of Medicine
#33
JOURNAL ARTICLE
Ryan Keen, Marilyn Winkleby
No abstract text is available yet for this article.
May 29, 2024: New England Journal of Medicine
#34
EDITORIAL
Pradeep Natarajan
No abstract text is available yet for this article.
May 29, 2024: New England Journal of Medicine
#35
JOURNAL ARTICLE
Robert S Rosenson, Daniel Gaudet, Robert A Hegele, Christie M Ballantyne, Stephen J Nicholls, Kathryn J Lucas, Javier San Martin, Rong Zhou, Ma'an Muhsin, Ting Chang, Jennifer Hellawell, Gerald F Watts
BACKGROUND: Angiopoietin-like 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases and hepatic uptake of triglyceride-rich lipoprotein remnants. ANGPTL3 loss-of-function carriers have lower levels of triglycerides, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and non-HDL cholesterol and a lower risk of atherosclerotic cardiovascular disease than noncarriers. Zodasiran is an RNA interference (RNAi) therapy targeting expression of ANGPTL3 in the liver...
May 29, 2024: New England Journal of Medicine
#36
JOURNAL ARTICLE
Bernard E Trappey
New England Journal of Medicine, Volume 390, Issue 20, Page 1845-1847, May 30, 2024.
May 30, 2024: New England Journal of Medicine
#37
JOURNAL ARTICLE
Christie M Ballantyne, Szilard Vasas, Masoud Azizad, Peter Clifton, Robert S Rosenson, Ting Chang, Stacey Melquist, Rong Zhou, Ma'an Mushin, Nicholas J Leeper, Jennifer Hellawell, Daniel Gaudet
BACKGROUND: Persons with mixed hyperlipidemia are at risk for atherosclerotic cardiovascular disease due to an elevated non-high-density lipoprotein (HDL) cholesterol level, which is driven by remnant cholesterol in triglyceride-rich lipoproteins. The metabolism and clearance of triglyceride-rich lipoproteins are down-regulated through apolipoprotein C3 (APOC3)-mediated inhibition of lipoprotein lipase. METHODS: We carried out a 48-week, phase 2b, double-blind, randomized, placebo-controlled trial evaluating the safety and efficacy of plozasiran, a hepatocyte-targeted APOC3 small interfering RNA, in patients with mixed hyperlipidemia (i...
May 28, 2024: New England Journal of Medicine
#38
JOURNAL ARTICLE
Katharina A Mayer, Eva Schrezenmeier, Matthias Diebold, Philip F Halloran, Martina Schatzl, Sabine Schranz, Susanne Haindl, Silke Kasbohm, Alexander Kainz, Farsad Eskandary, Konstantin Doberer, Uptal D Patel, Jaideep S Dudani, Heinz Regele, Nicolas Kozakowski, Johannes Kläger, Rainer Boxhammer, Kerstin Amann, Elisabeth Puchhammer-Stöckl, Hannes Vietzen, Julia Beck, Ekkehard Schütz, Aylin Akifova, Christa Firbas, Houston N Gilbert, Bilgin Osmanodja, Fabian Halleck, Bernd Jilma, Klemens Budde, Georg A Böhmig
BACKGROUND: Antibody-mediated rejection is a leading cause of kidney-transplant failure. The targeting of CD38 to inhibit graft injury caused by alloantibodies and natural killer (NK) cells may be a therapeutic option. METHODS: In this phase 2, double-blind, randomized, placebo-controlled trial, we assigned patients with antibody-mediated rejection that had occurred at least 180 days after transplantation to receive nine infusions of the CD38 monoclonal antibody felzartamab (at a dose of 16 mg per kilogram of body weight) or placebo for 6 months, followed by a 6-month observation period...
May 25, 2024: New England Journal of Medicine
#39
JOURNAL ARTICLE
Felicitas E Hengel, Silke Dehde, Moritz Lassé, Gunther Zahner, Larissa Seifert, Annabel Schnarre, Oliver Kretz, Fatih Demir, Hans O Pinnschmidt, Florian Grahammer, Renke Lucas, Lea Maxima Mehner, Tom Zimmermann, Anja M Billing, Jun Oh, Adele Mitrotti, Paola Pontrelli, Hanna Debiec, Claire Dossier, Manuela Colucci, Francesco Emma, William E Smoyer, Astrid Weins, Franz Schaefer, Nada Alachkar, Anke Diemert, Julien Hogan, Elion Hoxha, Thorsten Wiech, Markus M Rinschen, Pierre Ronco, Marina Vivarelli, Loreto Gesualdo, Nicola M Tomas, Tobias B Huber
BACKGROUND: Minimal change disease and primary focal segmental glomerulosclerosis in adults, along with idiopathic nephrotic syndrome in children, are immune-mediated podocytopathies that lead to nephrotic syndrome. Autoantibodies targeting nephrin have been found in patients with minimal change disease, but their clinical and pathophysiological roles are unclear. METHODS: We conducted a multicenter study to analyze antinephrin autoantibodies in adults with glomerular diseases, including minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, IgA nephropathy, antineutrophil cytoplasmic antibody-associated glomerulonephritis, and lupus nephritis, as well as in children with idiopathic nephrotic syndrome and in controls...
May 25, 2024: New England Journal of Medicine
#40
JOURNAL ARTICLE
Irene Frances, Maria Jose Muruzabal
New England Journal of Medicine, Volume 390, Issue 20, Page 1905-1905, May 30, 2024.
May 25, 2024: New England Journal of Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
